Welcome to our dedicated page for Dermata Therapeutics SEC filings (Ticker: DRMAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dermata Therapeutics SEC filings document the company's dermatology and skincare business, capital structure and governance as it operates with Nasdaq-listed common stock and warrants. Proxy materials cover shareholder voting matters, board and compensation governance, material agreements, operating and financial results, and security-structure disclosures.
Recent Form 8-K disclosures address changes in the independent registered public accounting firm, director resignation and board composition, prospectus supplements for at-the-market common stock sales, and capital-structure disclosures involving shares and warrants. The filings also include financial reporting and risk disclosures, including going-concern language in prior audit reports.
Dermata Therapeutics, Inc. reported that director Mary Fisher has notified the company she will resign from its Board of Directors, including all committee roles, effective March 31, 2026. The filing states her decision is tied to her employer’s recent acquisition, which will no longer permit her to serve on Dermata’s board.
The company notes that her resignation is not due to any disagreement with Dermata or its management regarding operations, policies, or practices. Once her resignation becomes effective, the size of the Board will be reduced from eight to seven members.
Dermata Therapeutics, Inc. reported that director Mary Fisher has notified the company she will resign from its Board of Directors, including all committee roles, effective March 31, 2026. The filing states her decision is tied to her employer’s recent acquisition, which will no longer permit her to serve on Dermata’s board.
The company notes that her resignation is not due to any disagreement with Dermata or its management regarding operations, policies, or practices. Once her resignation becomes effective, the size of the Board will be reduced from eight to seven members.
Dermata Therapeutics, Inc. investor update: Gerald T. Proehl filed Amendment No. 10 to his beneficial ownership report, stating that he may be deemed to beneficially own 694,687 shares of Dermata common stock. This represents 17.3% of the company’s outstanding common stock as of a recent share count.
The filing explains that his holdings include shares and options held directly, shares and warrants held through Proehl Investment Ventures LLC, and shares held by certain trusts for which he serves as trustee. The amendment also notes that there have been no purchases or sales of Dermata common stock or related convertible securities by him or entities he controls since a prior amendment earlier in 2026.
Dermata Therapeutics, Inc. investor update: Gerald T. Proehl filed Amendment No. 10 to his beneficial ownership report, stating that he may be deemed to beneficially own 694,687 shares of Dermata common stock. This represents 17.3% of the company’s outstanding common stock as of a recent share count.
The filing explains that his holdings include shares and options held directly, shares and warrants held through Proehl Investment Ventures LLC, and shares held by certain trusts for which he serves as trustee. The amendment also notes that there have been no purchases or sales of Dermata common stock or related convertible securities by him or entities he controls since a prior amendment earlier in 2026.
Dermata Therapeutics filing: Armistice Capital and Steven Boyd report shared beneficial ownership of 53,910 shares, representing 4.99% of common stock. The report, filed as a joint Schedule 13G/A, states Armistice Capital is investment manager to Armistice Capital Master Fund Ltd., which directly holds the shares, and that voting and dispositive power over the shares is exercised pursuant to an Investment Management Agreement. The Master Fund is identified as the direct holder and the filing notes the Master Fund "specifically disclaims beneficial ownership" due to its inability to vote or dispose of the securities under that agreement.
Dermata Therapeutics filing: Armistice Capital and Steven Boyd report shared beneficial ownership of 53,910 shares, representing 4.99% of common stock. The report, filed as a joint Schedule 13G/A, states Armistice Capital is investment manager to Armistice Capital Master Fund Ltd., which directly holds the shares, and that voting and dispositive power over the shares is exercised pursuant to an Investment Management Agreement. The Master Fund is identified as the direct holder and the filing notes the Master Fund "specifically disclaims beneficial ownership" due to its inability to vote or dispose of the securities under that agreement.
Dermata Therapeutics — Armistice Capital, LLC and Steven Boyd filed an amendment reporting beneficial ownership of 53,910 shares, representing 4.99% of the company's common stock. The filing states the reported percentage is based on information from the issuer and lists shared voting and dispositive power over those shares.
The filing explains Armistice Capital is investment manager to Armistice Capital Master Fund Ltd., the direct holder of the shares, and that Mr. Boyd, as managing member, may be deemed to beneficially own the securities. The Master Fund disclaims beneficial ownership due to the Investment Management Agreement. The joint filing is signed by Steven Boyd on 02/17/2026.
Dermata Therapeutics — Armistice Capital, LLC and Steven Boyd filed an amendment reporting beneficial ownership of 53,910 shares, representing 4.99% of the company's common stock. The filing states the reported percentage is based on information from the issuer and lists shared voting and dispositive power over those shares.
The filing explains Armistice Capital is investment manager to Armistice Capital Master Fund Ltd., the direct holder of the shares, and that Mr. Boyd, as managing member, may be deemed to beneficially own the securities. The Master Fund disclaims beneficial ownership due to the Investment Management Agreement. The joint filing is signed by Steven Boyd on 02/17/2026.
Dermata Therapeutics, Inc. received an amended Schedule 13G/A showing updated ownership by funds tied to Michael Bigger. As of February 9, 2026, Bigger Capital beneficially owned 239,103 shares of common stock, including 200,000 shares issuable upon exercise of pre-funded warrants. District 2 Capital Fund beneficially owned 61,000 shares. Based on 2,835,343 shares outstanding as of January 14, 2026 plus 200,000 pre-funded warrant shares, Bigger Capital and its general partner may be deemed to own 7.88% of the common stock, District 2-related entities 2.01%, and Michael Bigger approximately 9.89%. Large additional warrant positions are excluded due to shareholder approval requirements and 4.99% or 9.99% beneficial ownership limitations. The reporting persons certify the holdings are not for changing or influencing control of Dermata.
Dermata Therapeutics, Inc. received an amended Schedule 13G/A showing updated ownership by funds tied to Michael Bigger. As of February 9, 2026, Bigger Capital beneficially owned 239,103 shares of common stock, including 200,000 shares issuable upon exercise of pre-funded warrants. District 2 Capital Fund beneficially owned 61,000 shares. Based on 2,835,343 shares outstanding as of January 14, 2026 plus 200,000 pre-funded warrant shares, Bigger Capital and its general partner may be deemed to own 7.88% of the common stock, District 2-related entities 2.01%, and Michael Bigger approximately 9.89%. Large additional warrant positions are excluded due to shareholder approval requirements and 4.99% or 9.99% beneficial ownership limitations. The reporting persons certify the holdings are not for changing or influencing control of Dermata.
Dermata Therapeutics, Inc. filed an 8-K describing a change in its independent registered public accounting firm. On January 30, 2026, the company dismissed Baker Tilly US, LLP as auditor, effective January 31, 2026, following approval by the Audit Committee of the Board of Directors.
Baker Tilly’s audit reports for the years ended December 31, 2024 and 2023 contained no adverse or disclaimed opinions and were not qualified, other than an explanatory paragraph raising substantial doubt about Dermata’s ability to continue as a going concern. The company states there were no disagreements with Baker Tilly and no reportable events during those periods.
On February 2, 2026, the Audit Committee approved the appointment of CBIZ CPAs P.C. as Dermata’s new independent registered public accounting firm. CBIZ CPAs had previously served as Dermata’s auditor from 2016 to 2023, and the company reports no consultations with CBIZ CPAs on accounting or audit matters during 2024, 2023, or through January 31, 2026.
Dermata Therapeutics, Inc. filed an 8-K describing a change in its independent registered public accounting firm. On January 30, 2026, the company dismissed Baker Tilly US, LLP as auditor, effective January 31, 2026, following approval by the Audit Committee of the Board of Directors.
Baker Tilly’s audit reports for the years ended December 31, 2024 and 2023 contained no adverse or disclaimed opinions and were not qualified, other than an explanatory paragraph raising substantial doubt about Dermata’s ability to continue as a going concern. The company states there were no disagreements with Baker Tilly and no reportable events during those periods.
On February 2, 2026, the Audit Committee approved the appointment of CBIZ CPAs P.C. as Dermata’s new independent registered public accounting firm. CBIZ CPAs had previously served as Dermata’s auditor from 2016 to 2023, and the company reports no consultations with CBIZ CPAs on accounting or audit matters during 2024, 2023, or through January 31, 2026.
Dermata Therapeutics insider Gerald T. Proehl reports beneficial ownership of 694,576 shares of common stock, representing 19.6% of the company’s outstanding shares as of January 29, 2026. This percentage is based on 3,549,393 shares outstanding on that date.
The stake includes 24 shares and options for 1,763 shares held directly, 79,950 shares and 11 warrant shares held through Proehl Investment Ventures LLC, and 612,828 shares held by certain trusts where he is trustee. Some additional options and warrants are excluded because they do not vest or become exercisable within sixty days or require stockholder approval.
The filing states there have been no purchases or sales of Dermata common stock or related convertible securities by Proehl or entities he controls since the prior amendment filed on January 8, 2026.
Dermata Therapeutics insider Gerald T. Proehl reports beneficial ownership of 694,576 shares of common stock, representing 19.6% of the company’s outstanding shares as of January 29, 2026. This percentage is based on 3,549,393 shares outstanding on that date.
The stake includes 24 shares and options for 1,763 shares held directly, 79,950 shares and 11 warrant shares held through Proehl Investment Ventures LLC, and 612,828 shares held by certain trusts where he is trustee. Some additional options and warrants are excluded because they do not vest or become exercisable within sixty days or require stockholder approval.
The filing states there have been no purchases or sales of Dermata common stock or related convertible securities by Proehl or entities he controls since the prior amendment filed on January 8, 2026.
Dermata Therapeutics, Inc. filed a prospectus supplement on January 27, 2026 to increase the maximum aggregate offering amount of its common stock issuable under its existing at-the-market offering program with H.C. Wainwright & Co., LLC by an additional $705,000.
The company previously sold $3,454,390 of common stock under the same Sales Agreement and earlier prospectus supplements. The filing also includes a legal opinion from Lowenstein Sandler LLP covering the additional $705,000 of common stock, which is provided as an exhibit.
Dermata Therapeutics, Inc. filed a prospectus supplement on January 27, 2026 to increase the maximum aggregate offering amount of its common stock issuable under its existing at-the-market offering program with H.C. Wainwright & Co., LLC by an additional $705,000.
The company previously sold $3,454,390 of common stock under the same Sales Agreement and earlier prospectus supplements. The filing also includes a legal opinion from Lowenstein Sandler LLP covering the additional $705,000 of common stock, which is provided as an exhibit.
DRMA is updating its at-the-market stock offering program to allow additional sales of its common stock with an aggregate offering price of up to $705,000 through H.C. Wainwright & Co. under an existing Form S-3 shelf. This amount is in addition to approximately $3,454,390 of common stock previously sold under earlier prospectus supplements. The filing reflects the limits of General Instruction I.B.6 of Form S-3, which restricts primary offerings to no more than one-third of public float in any 12-month period while public float is below $75.0 million. The company reports a public float of about $7,493,999, based on 2,386,624 shares held by non-affiliates as of January 23, 2026, at a reference price of $3.14 per share, and notes that about $1,792,248 of securities have been sold under these limits in the last twelve months.
DRMA is updating its at-the-market stock offering program to allow additional sales of its common stock with an aggregate offering price of up to $705,000 through H.C. Wainwright & Co. under an existing Form S-3 shelf. This amount is in addition to approximately $3,454,390 of common stock previously sold under earlier prospectus supplements. The filing reflects the limits of General Instruction I.B.6 of Form S-3, which restricts primary offerings to no more than one-third of public float in any 12-month period while public float is below $75.0 million. The company reports a public float of about $7,493,999, based on 2,386,624 shares held by non-affiliates as of January 23, 2026, at a reference price of $3.14 per share, and notes that about $1,792,248 of securities have been sold under these limits in the last twelve months.
Dermata Therapeutics, Inc. is registering up to 6,207,730 shares of common stock for resale by existing investors under a Form S-3 registration statement. These shares include 1,484,312 common shares plus shares issuable upon exercise of 537,750 pre-funded warrants, 2,022,062 Series C warrants, 2,022,062 Series D warrants, and 141,544 placement agent warrants, all issued in a December 29, 2025 private placement. Dermata will not receive proceeds from stockholder resales but would receive cash only if the warrants are exercised, which it plans to use for working capital and general corporate purposes.
The company describes a major strategic shift from prescription dermatology to over-the-counter, science-backed products built on its Spongilla technology, with an initial once-weekly topical acne kit targeted for launch in mid-2026. Dermata also notes a 1-for-10 reverse stock split effective August 1, 2025 and highlights Nasdaq listings for its common stock and public warrants under the symbols “DRMA” and “DRMAW.”
Dermata Therapeutics, Inc. is registering up to 6,207,730 shares of common stock for resale by existing investors under a Form S-3 registration statement. These shares include 1,484,312 common shares plus shares issuable upon exercise of 537,750 pre-funded warrants, 2,022,062 Series C warrants, 2,022,062 Series D warrants, and 141,544 placement agent warrants, all issued in a December 29, 2025 private placement. Dermata will not receive proceeds from stockholder resales but would receive cash only if the warrants are exercised, which it plans to use for working capital and general corporate purposes.
The company describes a major strategic shift from prescription dermatology to over-the-counter, science-backed products built on its Spongilla technology, with an initial once-weekly topical acne kit targeted for launch in mid-2026. Dermata also notes a 1-for-10 reverse stock split effective August 1, 2025 and highlights Nasdaq listings for its common stock and public warrants under the symbols “DRMA” and “DRMAW.”